ALB and metastatic melanoma: A phase III randomized controlled clinical trial of albumin‐bound paclitaxel and dacarbazine in first‐line treatment of metastatic melanoma suggested a median PFS of 4.8 months for albumin‐bound paclitaxel, 2.5 months (p = 0.044), median OS of 12.6 months for albumin‐bound paclitaxel, 10.5 months (p = 0.271), and overall remission rates of albumin‐bound paclitaxine, 15% and 11% (p = 0.239).16